BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Synchronicity - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Synchronicity
X-ORIGINAL-URL:https://syncconference.org
X-WR-CALDESC:Events for Synchronicity
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260319T160000
DTEND;TZID=America/New_York:20260319T173000
DTSTAMP:20260507T031248
CREATED:20260120T153709Z
LAST-MODIFIED:20260121T174234Z
UID:10000127-1773936000-1773941400@syncconference.org
SUMMARY:Patient-Reported Outcomes in Clinical Trials Assessing the Effectiveness of Cabotegravir + Rilpivirine Long-Acting Injections as Antiretroviral Therapy: A Systematic Review
DESCRIPTION:Human immunodeficiency virus-1 (HIV-1) continues to have a high global burden\, with approximately 39.9 million people currently living with the virus. Despite the clinical success of antiretroviral therapy (ART)\, adherence remains a significant challenge\, often due to emotional distress and HIV-related stigma. Long-acting injectables (LAIs) such as the combination of cabotegravir (CAB) and rilpivirine (RPV) have emerged as promising alternatives\, reducing the burden of daily pill regimens. \nThis systematic review explores the role of CAB + RPV-LA injectables in antiretroviral therapy (ART)\, with a focus on patient-reported outcomes from five key clinical trials. \nFindings reveal that CAB + RPV-LA maintains high levels of viral suppression comparable to daily ART while improving patient satisfaction and quality of life. Meta-analysis of HIV Treatment Satisfaction Questionnaire (HIVTSQc) scores across multiple trials demonstrated consistent positive outcomes\, with a mean score of 28.83 out of a possible range from −33 to +33\, indicating a substantial improvement in patient satisfaction compared to baseline. Qualitative data highlight the psychological and logistical benefits of LAIs\, including reduced stigma and enhanced treatment convenience.
URL:https://syncconference.org/agenda/patient-reported-outcomes-in-clinical-trials-assessing-the-effectiveness-of-cabotegravir-rilpivirine-long-acting-injections-as-antiretroviral-therapy-a-systematic-review/
CATEGORIES:Track Session
ATTACH;FMTTYPE=image/jpeg:https://syncconference.org/wp-content/uploads/2026/01/TrackHero-HIVCareTreatment.jpg
END:VEVENT
END:VCALENDAR